Free Hematology CME

  • FREE

    Congenital Thrombotic Thrombocytopenic Purpura (CTTP): Updates from the American Society of Hematology (ASH) 2019 annual meeting

    Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder that impacts three in a million adults per year, with congenital or hereditary TTP (cTTP, also known as Upshaw-Schulman syndrome) accounting for a third of the overall incidence. The incidence of TTP rises with increasing age and the mortality rate of untreated TTP may be as high as 90%.

    In recent years molecular mechanisms contributing to TTP have been identified: patients diagnosed with TTP have larger von Willebrand factor molecules (vWF) and a defective protease enzyme of A Disintegrinlike And Metalloprotease with ThromboSpondin type 1 motif 13 (ADAMTS13), which cleaves larger vWF molecules and inhibits platelet adhesion. In congenital or hereditary TTP (cTTP, also known as Upshaw-Schulman syndrome), the gene that codes of ADAMTS13 is defective and cannot properly produce the enzyme, whereas in acquired TTP, antibody production leads to downstream enzymatic deactivation.

    Target Audience:
    The following healthcare professionals: hematologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with cTTP.

    By the end of the session the participant will be able to:

    • Summarize the most impactful findings presented at the ASH 2019 annual meeting relating to congenital TTP
    • Recall the pathophysiology of congenital TTP
    • Describe the clinical manifestations and methods of establishing a diagnosis of cTTP, and apply that information to a patient case
    • List treatment strategies for cTTP, and apply that information to a patient case
    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 08/30/2020
    • Expiration of CME credit: 08/30/2022
  • FREE

    Treating Oncology Patients During COVID-19

    Activity Description / Statement of Need: The COVID-19 pandemic has led to unprecedented changes in health care delivery worldwide, affecting the way that nearly every medical specialty can safely practice. As with other fields of medicine, oncology has its own challenges in navigating the pandemic. Based on pre-pandemic estimates, 1.8 million new cancer diagnoses would be expected in 2020, equating to approximately 5,000 new cancer diagnoses per day. Evidence thus far suggests that COVID-19 is associated with significantly more complications and a higher risk of death in patients with cancer or with a history of cancer. Furthermore, patients with cancer have also been shown to have a higher COVID-19 infection rate than the general population, suggesting increased susceptibility, potentially due to immunosuppression, comorbidities, or poor health status related to cancer or its treatment. Based on these data, oncology specialists are said to be fighting “a war on two fronts” by balancing the risks of COVID-19 transmission and acquisition with the risks of delayed cancer diagnosis and treatment. This represents an unmet need among oncology practitioners as they navigate this new health care landscape.

    Target Audience:

    Healthcare professionals, including medical oncologists; radiation oncologists; surgical oncologists; surgeons; radiologists; nuclear medicine specialists; nurse practitioners and physician assistants who practice in oncology; and other healthcare providers who manage cancer.

    By the end of the session the participant will be able to:

    • Recall the symptoms of COVID-19 infection and best practices for screening patients, health care providers, and staff in the oncology setting.
    • Develop a plan to provide oncology care in the setting of the COVID-19 pandemic.
    • Describe the risks of delaying cancer diagnosis and treatment against the risk of COVID-19 exposure and infection.
    • See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 09/22/2020
    • Expiration of CME credit: 09/22/2022
  • FREE

    Hemophilia B: Optimizing Pharmacotherapeutic Management Strategies

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia B is the same in all geographic regions, populations, and ethnic groups,affecting approximately 1 out of every 30,000 male births. The condition is diagnosed by measuring FIX activity, and patients with severe hemophilia have levels of 1% or less.

    Patients with severe hemophilia B are at risk for spontaneous, life-threatening bleeding episodes. Untreated, the life expectancy is approximately 20 years,and painful or even life-threatening morbidities include intracranial hemorrhage, severe bleeding in other organ systems, musculoskeletal injury, and joint injury. In contrast, in people with moderate or mild hemophilia, abnormal bleeding usually occurs after minor trauma or surgery.

    Physical therapy can ease symptoms if internal bleeding has damaged a patient’s joints, and surgery may be necessary if internal bleeding has caused severe damage. However, the current standard of therapy for hemophilia B is intravenous infusion of therapeutic factor concentrates. Through the reduction in the number of bleeding incidences and improvement in quality of life, factor replacement therapy has significantly reduced the morbidity and mortality of hemophilia. Furthermore, prophylactic therapy has the demonstrated benefit of reducing the development of hemophilic arthropathy.

    Target Audience:

    The following healthcare professionals: hematology, primary care physicians, and pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology as well as other Hemophilia Treatment Center HCPs; and any other clinicians with an interest in hemophilia B.

    By the end of the session the participant will be able to:

    • Describe the risk factors and occurrence of hemophilia B.
    • Identify available prophylactic and treatment options for hemophilia B and apply them to a patient case.
    • Identify the new treatment options for hemophilia B.
    • Identify adherence barriers in and deliver effective treatment counseling to patients with hemophilia B.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 06/10/2020
    • Expiration of CME credit: 06/10/2022
  • FREE

    Hemophilia A: Optimizing Pharmacotherapeutic Management Strategies

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia A, a mutation in the gene for factor VIII (FVIII) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia A is the same in all geographic regions, populations, and ethnic groups, affecting approximately 1 out of every 5000 male births. The condition is diagnosed by measuring FVIII activity, and patients with severe hemophilia have FVIII activity of 1% or less. Patients with severe hemophilia A are at risk for spontaneous, life-threatening bleeding episodes. Untreated, the life expectancy is approximately 20 years, and painful or even life-threatening morbidities include intracranial hemorrhage, severe bleeding in other organ systems, musculoskeletal injury, and joint injury. In contrast, in people with moderate or mild hemophilia, abnormal bleeding usually occurs after minor trauma or surgery.

    Target Audience:

    The following healthcare professionals: hematology, primary care physicians, and pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology as well as other Hemophilia Treatment Center HCPs; and any other clinicians with an interest in hemophilia A.

    By the end of the session the participant will be able to:

    • Describe the risk factors and occurrence of hemophilia A.
    • Identify available prophylactic and treatment options for hemophilia A and apply them to a patient case.
    • Identify the new treatment options for hemophilia A.
    • Identify adherence barriers in and deliver effective treatment counseling to patients with hemophilia A.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 06/06/2020
    • Expiration of CME credit: 06/06/2022
  • FREE

    Multiple Myeloma (MM): Updates from 23rd Annual Congress of EHA (EHA 2018)

    Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus.

    After completing Multiple Myeloma (MM): Updates from 23rd Annual Congress of EHA (EHA 2018) physicians will better be able to:

    • Summarize the most impactful findings presented at EHA 2018 meeting relating to initial treatment of transplant eligible and ineligible myeloma
    • Summarize the most impactful findings presented at EHA 2018 meeting relating to role of autologous stem cell transplant
    • Summarize the most impactful findings presented at EHA 2018 meeting relating to current role of monoclonal antibodies
    • Summarize the most impactful findings presented at EHA 2018 meeting relating to novel immune therapies

    Target Audience: hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: April 15, 2019
    • Expiration of CME credit: April 15, 2021
  • FREE

    Hemophilia A: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding.

    After completing Hemophilia A: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018) physicians will better be able to:

    • Describe the limitations of annual bleed rate as an epidemiological measure in Hemophilia A
    • Define early prophylaxis in severe hemophilia A and describe its impact on osteochondral damage
    • List evidence-supported benefits of extending clotting factor half lives
    • Summarize the most impactful findings presented at ASH 2018 meeting relating to prophylactic and therapeutic agents to treat hemophilia A, and apply them to patient cases
    • Describe the emerging therapies in the treatment of hemophilia A

     

    Target Audience:

    hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with Hemophilia A.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 04, 2019
    • Expiration of CME credit: March 04, 2021
  • FREE

    Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor

    After completing Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018) physicians will better be able to:

    • Describe the gene therapy and its anticipated impact on hemophilia B therapy
    • List evidence-supported benefits of switching to extended half-life / dose-interval clotting factors and apply that knowledge to patient cases
    • Summarize the most impactful findings presented at ASH 2018 meeting relating to prophylactic and therapeutic agents to treat hemophilia B, and apply** them to patient cases
    • Describe how immune modulation therapy may be used to induce immune tolerance to Factor IX inhibitors

    Target Audience: hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with hemophilia B.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 05, 2019
    • Expiration of CME credit: March 05, 2021
  • FREE

    Atypical hemolytic uremic syndrome (aHUS): therapeutic updates and optimizing treatment

    Atypical hemolytic uremic syndrome (aHUS) is a disease in which the complement system is activated in an uncontrolled manner outside the presence of coexisting disease, resulting in platelet activation, damage to endothelial cells, and a range of clinical sequelae including: which may ultimately lead to kidney failure; systemic thrombotic microangiopathy;anemia; and thrombocytopenia.

    After completing this course, you will better be able to:

    • Describe the pathophysiology of aHUS such that it might informs pairing with present treatment mechanisms
    • Describe aHUS diagnostic methods, differential diagnosis, and the benefits of earlier diagnosis
    • Describe available therapies used for treatment of aHUS and summarize the literature supporting use of those therapies
    • Design an evidence-based treatment plan for a patient with aHUS

    Target Audience: hematologists, nephrologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists specializing in hematology and transplant medicine; and any other healthcare professionals with an interest in or who may clinically encounter patients with aHUS.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 10, 2019
    • Expiration of CME credit: July 10, 2021
  • FREE

    Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Upshaw-Schulman syndrome): Therapeutic Updates, Best Practices, and Emerging Therapies

    Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder that impacts three in a million adults per year, with congenital or hereditary TTP (cTTP, also known as Upshaw-Schulman syndrome) accounting for a third of the overall incidence. The incidence of TTP rises with increasing age and the mortality rate of untreated TTP may be as high as 90%.

    After reviewing Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Upshaw-Schulman syndrome): Therapeutic Updates, Best Practices, and Emerging Therapies physiicians will be able to:

    • Describe the pathophysiology of cTTP such that it might inform treatment mechanisms.
    • Identify diagnostic criteria and differential diagnoses for cTTP
    • Describe current treatment standards for the management of cTTP and apply them to patient cases
    • Describe new and emerging therapies for the treatment of cTTP and the existing literature support its use in practice
    • Evaluate the likelihood cTTP in a patient case and develop a treatment plan

    Target Audience: hematologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with cTTP.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: October 02, 2018
    • Expiration of CME credit: October 02, 2020